Tags : Identification

Acceleron Signs a License Agreement with Fulcrum for the Identification

Shots: Fulcrum to receive $10M upfront, reimbursement for R&D costs, research, development and commercial milestone of up to $295M for first product commercialized and additional payments $143.5M for all subsequent products commercialized plus royalties on sales of product Acceleron to get rights to access Fulcrum’s product engine and target identification platform for identifying small molecule […]Read More

Roche Reports Launch of First CDx VENTANA PD-L1 (SP142) Assay

Shots: The launch of VENTANA PD-L1 (SP142) follows the US FDA’s approval in Mar’2019, as the first CDx assay involved in identifying triple-negative breast cancer (TNBC) patients associated with 3 proteins estrogen receptor, progesterone receptor and HER2/neu eligible for treatment with Tecentriq combination The assay is developed for the enhancement of visual contrast of tumor-infiltrating […]Read More

Roche Launches Ventana HER2 Dual ISH CDx for the Identification

 Shots: Roche’s Ventana HER2 Dual ISH DNA Probe Cocktail assay is used to detect HER2 biomarker in breast and gastric cancer patients receiving Herceptin (trastuzumab) The approval of Ventana HER2 Dual ISH assay supports Roche’s personalized healthcare sector by providing techniques to diagnose breast and gastric cancer The Ventana HER2 assay is fully automated on […]Read More